Immu was purchase at a premium of just over 100% o
Post# of 148155
See below
Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Immunomedics’ common stock. The $88.00 per share acquisition price represents a 108 percent premium to Immunomedics’ closing price on September 11, 2020.
https://www.gilead.com/news-and-press/press-r...munomedics
IMO